Watch Video from the World TB Day Congressional Briefing

World TB Day Congressional Briefing

Tuberculosis – We Can Beat this Global Killer

Wednesday, March 21, 2012

A briefing and update on tuberculosis (TB), a disease that is curable but still takes the lives of 4,000 people each day and is the number one killer of people living with HIV. Special areas of focus of the briefing include US global leadership on TB, how communities are addressing the crisis, the threat of drug-resistant TB, and progress towards an effective vaccine, better medications and faster diagnostics.

Moderator: John Fawcett, Legislative Director, RESULTS Educational Fund

Video Part One:

Video Part Two:

Video Part Three:


Ariel Pablos-Mendez, Assistant Administrator for Global Health at the U.S. Agency for International Development (USAID)

US Partnership in Advancing the Response to TB



Carol Nyirenda, Executive Director of the Community Initiative for Tuberculosis ( TB), HIV/AIDS and Malaria plus related diseases (CITAM +), Zambia

African Leadership at all Levels Confronting TB and TB-HIV



Jennifer Woolley, Director of Advocacy, Aeras

New Tools for TB: Investing in Long-Term Solutions



Dr. Lucica Ditiu, Executive Secretary, Stop TB Partnership

US leadership is crucial in winning the TB battle


Co-sponsored by RESULTS Educational Fund, American Thoracic Society, Stop TB Partnership, Aeras, and Treatment Action Group

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...